| Literature DB >> 26197313 |
Luciana Nalone Andrade1, Tamires Cardoso Lima2, Ricardo Guimarães Amaral3, Cláudia do Ó Pessoa4, Manoel Odorico de Moraes Filho5, Bruno Marques Soares6, Lázaro Gomes do Nascimento7, Adriana Andrade Carvalho8, Damião Pergentino de Sousa9.
Abstract
Compounds isolated from essential oils play an important role in the prevention and treatment of cancer. Monoterpenes are natural products, and the principal constituents of many essential oils. The aim of this study was to investigate the cytotoxic potential of p-menthane derivatives. Additionally, analogues of perillyl alcohol, a monoterpene with known anticancer activity, were evaluated to identify the molecular characteristics which contribute to their cytotoxicity, which was tested against OVCAR-8, HCT-116, and SF-295 human tumor cell lines, using the MTT assay. The results of this study showed that (-)-perillaldehyde 8,9-epoxide exhibited the highest percentage inhibition of cell proliferation (GI = 96.32%-99.89%). Perillyl alcohol exhibited high cytotoxic activity (90.92%-95.82%), while (+)-limonene 1,2-epoxide (GI = 58.48%-93.10%), (-)-perillaldehyde (GI = 59.28%-83.03%), and (-)-8-hydroxycarvotanacetone (GI = 61.59%-94.01%) showed intermediate activity. All of the compounds tested were less cytotoxic than perillyl alcohol, except (-)-perillaldehyde 8,9-epoxide (IC50 = 1.75-1.03 µL/mg). In general, replacement of C-C double bonds by epoxide groups in addition to the aldehyde group increases cytotoxicity. Furthermore, stereochemistry seems to play an important role in cytotoxicity. We have demonstrated the cytotoxic influence of chemical substituents on the p-menthane structure, and analogues of perillyl alcohol.Entities:
Keywords: anticancer; antitumoral; cytotoxic activity; cytotoxicity; essential oils; monoterpenes; natural products; p-menthane; perillyl alcohol
Mesh:
Substances:
Year: 2015 PMID: 26197313 PMCID: PMC6331850 DOI: 10.3390/molecules200713264
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structures of evaluated compounds.
Cell growth inhibition percentage of compounds tested at the concentration of 25 μg/mL against tumor cell lines.
| Compounds | Cells | |||||
|---|---|---|---|---|---|---|
| HCT-116 | SD | OVCAR-8 | SD | SF-295 | SD | |
| IG% | IG% | IG% | ||||
| (−)-Carvone ( | ±2.54 | ±1.38 | ±1.13 | |||
| (+)-Carvone ( | ±2.46 | ±1.20 | ±3.47 | |||
| (−)-8-Hydroxycarvotanacetone ( | ±2.62 | ±1.38 | ±3.10 | |||
| (+)-8-Hydroxycarvotanacetone ( | ±1.85 | ±2.96 | ±1.07% | |||
| (−)-Carvone epoxide ( | ±1.00 | ±0.49 | ±0.06 | |||
| (+)-Carveol epoxide ( | ±4.31 | ±8.58 | ±2.44 | |||
| (−)-
| ±2.38 | ±9.96 | ±1.19 | |||
| (−)-8-Acetoxycarvotanacetone ( | ±9.38 | ±1.58 | ±3.51 | |||
| (+)-Pulegone ( | ±5.85 | ±8.08 | ±9.95 | |||
| (
| ±2.31 | ±10.45 | ±6.43 | |||
| (−)-
| ±5.08 | ±0.89 | ±6.73 | |||
| (+)-Limonene 1,2-epoxide ( | ±2.77 | ±0.10 | ±1.07 | |||
| (−)-Sobrerol ( | ±7.24 | ±4.20 | ±3.57 | |||
| (
| ±0.30 | ±7.06 | ±0.39 | |||
| (−)-Perillaldehyde ( | ±1.54 | ±1.43 | ±5.78 | |||
| (−)-Perillaldehyde 8,9-epoxide ( | ±0.74 | ±1.51 | ±0.24 | |||
| (−)-Perillyl acetate ( | ±5.38 | ±2.34 | ±4.32 | |||
| (
| ±2.67 | ±1.72 | ±2.13 | |||
| Doxorubicin | ±0.15 | ±0.63 | ±0.31 | |||
Cell lines: OVCAR-8 (ovarian adenocarcinoma), HCT-116 (colon carcinoma), and SF-295 (glioblastoma) humans. GI% values are presented as the mean ± SD of three independent experiments measured by the MTT assay after 72 h of incubation. All compounds were tested at a concentration of 25 μg/mL. Doxorubicin was used as the positive control.
Cytotoxic activity of (−)-perillaldehyde 8,9-epoxide and (−)-8-hydroxycarvotanacetone on tumor cell lines. Experiments were performed in triplicate.
| Cells | Doxorubicin µg/mL | (−)-Perillaldehyde 8,9-epoxide µg/mL | (−)-8-Hydroxycarvotanacetone µg/mL |
|---|---|---|---|
| 0.01 | 1.03 | 1.08 | |
| 1.20 | 1.15 | 1.44 | |
| 0.24 | 1.75 | 3.24 | |
| 0.02 | 0.64 | ____ |
Cell lines: OVCAR-8 (ovarian adenocarcinoma), HCT-116 (colon carcinoma), SF-295 (glioblastoma), and HL-60 (leukemia) humans. Data are presented as IC50 values (μg/mL) and their 95% confidence interval obtained by non-linear regression from three independent experiments performed in triplicate, measured by the MTT assay after 72 h of incubation. Doxorubicin was used as the positive control.
Figure 2Effect of 16 on leukemic cell (HL-60) proliferation as measured by the trypan blue dye exclusion method after 24 h of incubation. The negative control was treated with the same vehicle (NC, 0.1% DMSO) used for diluting the test substance. Doxorubicin (PC, 0.3 µg/mL) was used as the positive control. Data are presented as mean values ± S.E.M. of two or three independent experiments performed in duplicate. * p < 0.05 compared to negative control by ANOVA followed by Student-Newman-Keuls test.
Figure 3The effect of 16 on the viability of human leukemic cells (HL-60). Cell viability (viable cells-black bar; apoptotic cells-gray bar; and necrotic cells-white bar) was determined respectively by fluorescence microscopy using acridine orange/ethidium bromide after 24-h incubations. The data are presented as the mean values ± S.E.M. of three independent experiments performed in duplicate. The negative control was treated with the same vehicle (NC, 0.1% DMSO) that diluted the test substance. Doxorubicin (PC, 0.3 μg/mL) served as the positive control. * p < 0.05 compared to negative control by ANOVA, followed by a Student Newman-Keuls test.
Figure 4Effect of 16 on cell morphology for HL-60 human leukemia cells. The cells were stained with hematoxylin-eosin and analyzed by optical microscopy after 24 h incubation at concentrations of 0.32 (C); 0.64 (D); and 1.28 μg/mL (E). Negative control (A) was treated with the vehicle (0.1% DMSO) used for diluting the test substance. Doxorubicin (0.3 μg/mL) was used as the positive control (B). Continuous arrows show nuclear fragmentation and non-continuous arrows show accumulation of metaphases cells.